Swetha Kambhampati, M.D.

Swetha Kambhampati, M.D., sees her calling as a physician as the perfect way to combine her love for science with her passion for service. She aims to provide compassionate care tailored to each patient's needs. As an oncologist/hematologist specializing in lymphoma, she has experience and expertise in novel immunotherapies, CAR T cell therapy and stem cell transplantation. Her research is focused on developing and evaluating novel immunotherapies and targeted therapies for the treatment of non-Hodgkin and Hodgkin lymphoma. She is a co-investigator on a variety of leading-edge trials for lymphoma and collaborates with leading lymphoma scientists to identify biomarkers predictive of response and resistance to therapies, in an effort to better personalize treatments for patients.

Dr. Kambhampati received her medical degree from Stanford University and pursued her internal medicine residency training at Johns Hopkins Hospital and hematology/oncology fellowship at University of California San Francisco. She completed an advanced fellowship focusing on lymphoma at City of Hope prior to joining the faculty in 2022. She has over 25 peer-reviewed scientific publications to her credit, including publications in top journals such as Blood and Blood Advances. She was recognized by the American Society of Clinical Oncology with a Young Investigator Award and Conquer Cancer Merit Award, and she was selected as an American Society of Hematology Clinical Research Training Institute Scholar.

When not treating patients or conducting research, Dr. Kambhampati enjoys singing, traveling, hiking, exploring new restaurants and spending time with family.

Awards

• 2023, Lymphoma Research Foundation Lymphoma Scientific Research Mentoring Program Scholar
• 2022, ASCO Conquer Cancer Merit Award
• 2021-2022, FDA-AACR Oncology Educational Fellowship
• 2021-2022, ASCO Young Investigator Award
• 2021, ASH Research Training Award for Fellows Finalist
• 2021, Multiple Myeloma Research Foundation Research Fellow Award
• 2020, ASH Abstract Achievement Award
• 2020-2021, ASH Clinical Research Training Institute Scholar
• 2020, ASCO FDA Workshop Selected Candidate
• 2019, Society for Translational Oncology Fellows’ Forum Scholar
• 2019, ASCO/AACR Methods in Clinical Cancer Research Workshop Selected Attendee
• 2018, UCSF Hematology/Oncology Annual Research Retreat Best Poster Award
• 2011, Klingenstein Fellow
• 2010, All USA Today 2010 College Academic Team
• 2010, Rhodes Scholarship Finalist
• 2010, Phi Beta Kappa Society
• 2010, Merage American Dream Fellowship
• 2010, Sigma Xi Honor Society
• 2009-2010, Leaders in Global Health Transformation
• 2009, Amgen Research Scholar
• 2009, Student Leaders in Service: AmeriCorps “Education Award Only” Program
• 2009, National Society of Collegiate Scholars Exemplary Scholar Award
• 2009, Johnson and Johnson Bioengineering Research Award
• 2008-2009, Emerson Music Scholar
• 2006, Co-Guest Editor of Up Your Score: The Underground Guide to the SAT

Memberships

• 2021, American Society for Transplantation and Cellular Therapy
• 2018, American Society of Clinical Oncology
• 2018, American Society of Hematology
• 2013, American College of Physicians

• Kambhampati S, Zain J. ctDNA in Lymphoma. 2022 August. Current Hematologic Malignancy Reports. 2022 August. Accepted.
• Kambhampati S, Saumoy M, Schneider Y, Serrao S, Solaimani P, Budde L, Mei M, Popplewell L, Siddiqi T, Zain J, Forman S, Kwak L, Rosen S, Danilov A, Herrera A, Thiruvengadam N. Cost Effectiveness of Second line Axicabtagene ciloleucel in Relapsed Refractory Diffuse Large B-cell Lymphoma. Blood. 2022 July. PMID: 35914220.
• Kambhampati S, Saumoy M, Schneider Y, Pak S, Budde L, Mei M, Popplewell L, Siddiqi T, Wen Y, Zain J, Forman S, Kwak L, Rosen S, Danilov A, Herrera A, Thiruvengadam N. Cost Effectiveness of Polatuzumab Vedotin Combined with Chemoimmunotherapy in Untreated Diffuse Large B-cell Lymphoma. Blood. 2022 June. PMID: 35700381.
• Kambhampati S, Mei M, Godfrey J, Siddiqi T, Salhotra A, Chen R, Smith E, Popplewell L, Herrera A. PD-1 Blockade after Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma. Clinical Lymphoma, Myeloma, and Leukemia. 2022 June. PMID: 35778267.
• Kambhampati S, Shing Y, Huang CY, Bylsma S, Lo M, Martin T, Wolf J, Shah N, Wong S. Infectious Complications in Relapsed Refractory Multiple Myeloma Patients after BCMA CAR T Therapy. Blood Advances. 2022 April. PMID: 34543400.
• Ladbury C,* Kambhampati S,* Othman T, Hao C, Chen L, Wong J, Cao T, Herrera A, Mei M, Dandapani S. Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B cell Lymphoma Post Autologous Stem Cell Transplant. International Journal Radiation Oncology, Biology, Physics. 2022 Feb. PMID: 35176414. *First two authors contributed equally and are co-first authors
• Kambhampati S, Song J, Herrera A, Chan W. Barriers to Achieving a Cure in Lymphoma. Cancer Drug Resistance. 2021 November. PMID: 35582375. DOI: 10.20517/cdr.2021.66.
• Kennedy V, Wong C, Huang, CY, Kambhampati S, Wolf J, Martin T, Shah N, Wong S. Macrophage Activation Syndrome-Like Manifestation (MAS-L) Following BCMA-directed CAR T-cells in Multiple Myeloma. Blood Advances. 2021 October. PMID: 34644387.
• Banerjee R, Marsal J, Huang CY, Lo M, Kambhampati S, Kennedy V, Arora S, Wolf J, Martin T, Wong S, Shah N. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2021 March. PMID: 33831353.
• Kambhampati S, Fakhri B, Ai W, Kalan L, Tuscano J, Wieduwilt M, Sudhindra A, Cavallone E, Reiner J, Martinelli M, Aoun C, Ta T, Le D, Padilla M, Crawford E, Andreadis C. Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clinical Lymphoma, Myeloma, Leukemia. 2020 Dec. PMID: 33478921.
• Parks A, Kambhampati S, Fakhri B, Andreadis C, Gray L, Wong S, Shah N, Fang M. Incidence, Management, and Outcomes of Arterial and Venous Thrombosis after Chimeric Antigen Receptor Modified T Cells for B Cell Lymphoma and Multiple Myeloma. Leukemia and Lymphoma. 2020 Dec. 1:1-6. doi: 10.1080/10428194.2020.1852474. PMID: 33258699.
• Lee D, Kambhampati S, Mohammed M, Goli R, Thiemann D, Lawson B, Resar J, Mohanty B. Erratum to: Efficacy of Coronary Computed Tomography Angiography for the De Novo Detection of Chronic Total Occlusion Prior to Coronary Angiography: A Preliminary and Retrospective Study. Int J Angiol. 2020 Dec. PMID: 33679116.
• Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai W, Pampaloni M, Huang C, Martin T. Damon L, Andreadis C. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma, Leukemia. 2020 Nov. 11:S2152-2650(20)30629-7. doi: 10.1016/j.clml.2020.11.005. PMID: 33288485.
• Kambhampati S, Tieu AH, Luber B, Wang H, Meltzer SJ. Risk Factors for Progression of Barrett's Esophagus to High Grade Dysplasia and Esophageal Adenocarcinoma. Scientific Reports. 2020 Mar 17;10(1):4899. doi: 10.1038/s41598-020-61874-7. PubMed PMID: 32184470; PubMed Central PMCID: PMC7078316.
• Kambhampati S, Galligan D, Huang C, Wong S, Wolf J, Martin T, Shah N. A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma. Leukemia and Lymphoma. 2020 Jan. doi: 10.1080/10428194.2019.1709835. PMID 31928108. 
• Kambhampati S, Bauer K, Bracci P, Keenan B, Behr S, Gordan J, Kelley K. Nivolumab in Advanced Hepatocellular Carcinoma and Child Pugh B Cirrhosis: Safety and Clinical Outcomes in a Retrospective Case Series. Cancer. 2019 April 29. CNCR-19-0529.R1. PMID 31154669
• Wang Z*, Kambhampati S*, Cheng Y*, et al. Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett’s Esophagus: A Prospective Validation Study. Clinical Cancer Research. 2019 April. 1;25(7):2127-2135. doi: 10.1158/1078-0432.CCR-18-3696. PMID: 30670490. *First three authors contributed equally and are co-first authors.
• Orimoloye OA, Kambhampati S, Hicks AJ 3rd, Al Rifai M, et al. Higher cardiorespiratory fitness predicts long-term survival in patients with heart failure and preserved ejection fraction: the Henry Ford Exercise Testing (FIT) Project. Arch Med Sci. 2019 Mar;15(2):350-358. doi: 10.5114/aoms.2019.83290. PMID: 30899287
• Hsu S, Kambhampati S, Sciortino CM, Russell SD, Schulman SP. Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock. Am Heart J. 2018 May; 199:181-191. PMID: 29754660.
• Kambhampati S, Ashvetiya T, Stone NJ, Blumenthal RS, Martin SS. Shared Decision-Making and Patient Empowerment in Preventive Cardiology. Curr Cardiol Rep 2016;18:49. PMID: 27098670.
• Moran RA, Jalaly NY, Kamal A, Rao S, Klapheke R, James TW, Kambhampati S, Makary MA, Hirose K, Kumbhari V, Stein EM, Khashab MA, Lennon AM, Kalloo AN, Zaheer A, Hernaez R, Singh VK. Ileus is a predictor of local infection in patients with acute necrotizing pancreatitis. Pancreatology. 2016;16(6):966-972. PMID: 27727097.
• Rizal RE, Mediratta RP, Xie J, Kambhampati S, Hills-Evans K, Montacute T, Pischel L. Galvanizing medical students in the administration of influenza vaccines: the Stanford Flu Crew. Advances in Medical Education and Practice. 2015;6:471-477. PMID: 26170731.
• Kambhampati S, Park W, Habtezion A. Pharmacologic therapy for acute pancreatitis. World Journal of Gastroenterology: WJG. 2014;20(45):16868-16880. PMID: 25493000.
• Ghebremariam YT, Huang NF, Kambhampati S, Volz KS, Joshi GG, Anslyn EV, Cooke JP. Characterization of a fluorescent probe for imaging nitric oxide. Journal of Vascular Research. 2014;51(1):68-79. PMID: 24335468.
• Kastrup CJ, Nahrendorf M, Figueiredo JL, Lee H, Kambhampati S, Lee T, Cho SW, Gorbatov R, Iwamoto Y, Pritchard CD, Vegas AJ, Siegl CD, MacDougall S, Stone JR, Coury AJ, Weissleder R, Langer R, Anderson DG. Painting Blood Vessels and Atherosclerotic Plaques with an Adhesive Drug Depot. PNAS. 2012 Dec 26;109(52):21444-9. PMID: 23236189.